| |
|
 |
Hemoccult
® SENSA®
Products |
| Increased Clinical Sensitivity
and Improved Readablity. |
 |
 |
|
|
Product
Effectiveness |
| |
The
detection of occult blood in stool using Hemoccult
SENSA, a more sensitive and readable test than
regular Hemoccult, is a highly effective method
for detecting bleeding associated with colorectal
cancer and adenomas.
Prospective, randomized controlled clinical
trials extending for up to 18 years have demonstrated
that the Hemoccult products are effective in
detecting occult blood in stool as an early
indication colorectal cancer.
In clinical trials that enrolled over 339,000
individuals, mortality from colorectal cancer
was reduced up to 33% when fecal occult blood
tests were performed annually3-5
and 15-21% when performed biennially6. The program
sensitivity for detecting colorectal cancer
when Hemoccult was performed annually was 90%.7,8
Hemoccult SENSA Single Slides
are convenient for use when single fecal specimens
are collected for routine in-office gastrointestinal
screening.
Hemoccult II SENSA Slides are designed
so patients can collect serial specimens at
home from bowel movements over three days. After
the patient prepares the Hemoccult II SENSA
test, it may be returned in person or by mail
(using the Hemoccult Mailing Pouch) to the laboratory,
hospital or medical office for developing and
interpretation.
The Hemoccult SENSA tests consist of
two main components:
| 1.
|
Hemoccult
SENSA Slides (Test Cards) containing
guaiac paper
|
| 2.
|
Hemoccult
SENSA Developer, a developing
solution containing a stabilized mixture
of less than 4.2% hydrogen peroxide and
80% denatured ethyl alcohol and enhancer
in an aqueous solution. |
Polyps and cancer may bleed
intermittently. Hemoccult II SENSA triple slide
products are designed so patients can collect
serial specimens over three days. This increases
the probability of detecting hidden blood from
polyps and cancer. |
 |
|
|
|
Hemoccult
SENSA Product Links |
| |
|
|
| |
If you would like free samples or have a representative
call you please contact:
1-800-877-6242 or 650-845-3526,
or email us at askpcd@beckman.com
|
|
|
Footnotes:
1. Data
on file, Product Development department, Beckman
Coulter, Inc., Primary Care Diagnostics (formerly
SmithKline Diagnostics).
2. Baker, J., et al.: "Readability and
sensitivity of two guaiac-based fecal occult
blood tests," Gastroenterol. 94(5):A5,
1988.
3. Hardcastle, J.D., et al.: "Randomised
controlled trial of faecal-occult-blood screening
for colorectal cancer," Lancet. 348:1471-1477,
1996.
4. Kronborg, O., et al.: "Randomised study
of screening for colorectal cancer with faecal-occult-blood
test," Lancet. 348:1467-1471, 1996.
5. Mandel, J.S., et al.: "Reducing mortality
from colorectal cancer by screening for fecal
occult blood," N Eng J Med. 328:1365-1371,
1993.
6. Mandel, J.S., et al.: "Colorectal cancer
mortality: Effectiveness of biennial screening
for fecal occult blood," J Natl Cancer
Inst. 91:434-437, 1999.
7. Ederer, F., et al.: "Fecal occult blood
screening in the Minnesota Study:Role of chance
detection of lesions," JNatl Cancer Inst.89:1423-1428,
1997.
8. Church, T.R., et al.: "Fecal occult
blood screening in the Minnesota Study: Sensitivity
of the screening test," J Natl Cancer Inst.
91:1440-1448, 1997.
|
 |
|
|
|
|
|
|
|
 |